» Articles » PMID: 28763468

Predictors of Lung Function Test Severity and Outcome in Systemic Sclerosis-associated Interstitial Lung Disease

Abstract

Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in SSc. In this study, we aimed to describe the baseline severity and evolution of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) in patients with SSc-ILD and to assess the baseline clinical, biological and high-resolution CT scan (HRCT) predictors of this evolution. Baseline and serial FVC and DLCO were collected in 75 SSc-ILD patients followed during 6.4±4.2 years (n = 557 individual data). FVC and DLCO evolution was modelled using a linear mixed model with random effect. During follow-up, FVC was stable while DLCO significantly decreased (-1.5±0.3%/year (p<0.0001). Baseline NYHA functional class III/IV, extensive SSc-ILD on HRCT and DLCO<80% were associated with a lower baseline FVC. Absence of digital ulcers extensive SSc-ILD, and FVC<80% and were associated with a lower baseline DLCO. Presence or history of digital ulcers and presence of pulmonary hypertension at baseline or during follow-up were associated with a faster decline of DLCO overtime. Neither age, gender, subtype of SSc nor specificity of autoantibodies were associated with baseline severity or outcome of lung function tests. In this SSc-ILD population, FVC was therefore stable while DLCO significantly declined over time. ILD extension was associated with baseline FVC and DLCO but not with their evolution. Presence or history of digital ulcers and pulmonary hypertension were predictors of a faster decline of DLCO over time.

Citing Articles

Transthoracic Lung Ultrasound in Systemic Sclerosis-Associated Interstitial Lung Disease: Capacity to Differentiate Chest Computed-Tomographic Characteristic Patterns.

Rotondo C, Busto G, Rella V, Barile R, Cacciapaglia F, Fornaro M Diagnostics (Basel). 2025; 15(4).

PMID: 40002639 PMC: 11854868. DOI: 10.3390/diagnostics15040488.


The Value of Ultrasound for Detecting and Following Subclinical Interstitial Lung Disease in Systemic Sclerosis.

Gutierrez M, Bertolazzi C, Zozoaga-Velazquez E, Clavijo-Cornejo D Tomography. 2024; 10(4):521-532.

PMID: 38668398 PMC: 11054173. DOI: 10.3390/tomography10040041.


Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.

Petelytska L, Bonomi F, Cannistra C, Fiorentini E, Peretti S, Torracchi S RMD Open. 2023; 9(4).

PMID: 37940340 PMC: 10632935. DOI: 10.1136/rmdopen-2023-003426.


The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease.

Martin-Lopez M, Carreira P J Clin Med. 2023; 12(20).

PMID: 37892818 PMC: 10607647. DOI: 10.3390/jcm12206680.


Self-Reported Systemic Sclerosis-Related Symptoms Are More Prevalent in Subjects with Raynaud's Phenomenon in the Lifelines Population: Focus on Pulmonary Complications.

van de Zande S, Abdulle A, Al-Adwi Y, Stel A, de Leeuw K, Brouwer E Diagnostics (Basel). 2023; 13(13).

PMID: 37443554 PMC: 10340274. DOI: 10.3390/diagnostics13132160.


References
1.
Mihai C, Landewe R, van der Heijde D, Walker U, Constantin P, Gherghe A . Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. 2015; 75(4):681-6. DOI: 10.1136/annrheumdis-2014-205897. View

2.
Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

3.
Clements P, Roth M, Elashoff R, Tashkin D, Goldin J, Silver R . Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007; 66(12):1641-7. PMC: 2095310. DOI: 10.1136/ard.2007.069518. View

4.
Bouros D, Wells A, Nicholson A, Colby T, Polychronopoulos V, Pantelidis P . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165(12):1581-6. DOI: 10.1164/rccm.2106012. View

5.
LeRoy E, Medsger Jr T . Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001; 28(7):1573-6. View